Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Patient-reported Tolerability of Adjuvant Ipilimumab (3 or 10 Mg/kg) Versus High-Dose Interferon Alfa-2B for Resected High-Risk Stage III–IV Melanoma in Phase III Trial E1609

Laurie E. McLouth,Yue Zheng,Stephanie Smith,F. Stephen Hodi,Uma N. Rao,Gary I. Cohen,Thomas T. Amatruda,Shaker R. Dakhil,Brendan D. Curti,Ibrahim Nakhoul,Sreenivasa R. Chandana,Charles L. Bane,David E. Marinier,Sandra J. Lee,Vernon K. Sondak,John M. Kirkwood,Ahmad A. Tarhini,Lynne I. Wagner

QUALITY OF LIFE RESEARCH（2023）

Cited 0|Views8
Key words
Ipilimumab,Melanoma,Adjuvant therapy,Interferon,Patient-reported outcomes,Quality of life
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined